Prime Medicine (PRME) Operating Leases (2021 - 2026)

Prime Medicine has reported Operating Leases for 6 years, with the latest figure at $114.5 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Leases rose 45.69% year-over-year to $114.5 million; the trailing twelve-month figure through Mar 2026 stood at $114.5 million (up 45.69% YoY), and the FY2025 full-year result was $108.3 million, up 191.26% from the prior year.
• Operating Leases for Q1 2026 stood at $114.5 million, up from $108.3 million in the prior quarter.
• The five-year high for Operating Leases was $114.5 million in Q1 2026, with the low at $4.4 million in Q4 2023.
• Historically, Operating Leases has averaged $50.8 million across 5 years, with a median of $33.6 million in 2024.
• Annual changes were most pronounced in 2023 — Operating Leases plunged 74.45% — and 2024, when it surged 753.34%.
• Prime Medicine's Operating Leases stood at $17.1 million in 2022, then sank by 74.45% to $4.4 million in 2023, then surged by 753.34% to $37.2 million in 2024, then surged by 191.26% to $108.3 million in 2025, then rose by 5.75% to $114.5 million in 2026.
• The last three Operating Leases figures came in at $114.5 million (Q1 2026), $108.3 million (Q4 2025), and $110.4 million (Q3 2025), per Business Quant data.